Preliminary experience of maintenance treatment with intravenous ustekinumab as a rescue treatment for loss of response to subcutaneous doses

Rev Esp Enferm Dig. 2021 Mar;113(3):186-188. doi: 10.17235/reed.2020.7230/2020.

Abstract

It has been demonstrated that ustekinumab (UST) is effective as an induction and maintenance therapy in patients with Crohn's disease (CD). However, a significant number of patients experience an insufficient response or a secondary non-response. We report six cases from our center that underwent a rescue treatment by changing maintenance treatment to weight-adjusted intravenous UST, obtaining a subsequent clinical improvement.

MeSH terms

  • Administration, Intravenous
  • Crohn Disease* / drug therapy
  • Humans
  • Induction Chemotherapy
  • Remission Induction
  • Ustekinumab* / therapeutic use

Substances

  • Ustekinumab